CMMB

Chemomab Therapeutics Ltd. [CMMB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CMMB Stock Summary

EPS has been decreasing for the past 3 years (Yearly statements)

Currently unprofitable, and not expected to turn profitable in the coming year

Does not have any significance market cap ($6.08M)

CMMB has less than 1 year of cash runway

Top 10 Correlated ETFs

CMMB

Top 10 Correlated Stocks

CMMB

In the News

01:32 10 Dec 2023 CMMB

Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC

The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.

11:20 10 Dec 2023 CMMB

Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Adi Mor - Co-Founder and Chief Scientific Officer Matt Frankel - Chief Medical Officer, Vice President of Drug Development Don Marvin - Chief Financial Officer, Executive Vice President & Chief Operating Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab Therapeutics First Quarter 2023 Earnings Call and Corporate Update.

07:00 10 Dec 2023 CMMB

Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference

TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday March 15, 2023.

11:43 10 Dec 2023 CMMB

Chemomab (CMMB) Stock Gains 30% on FDA Clearance

There's potentially positive news for the medical community as well as investors of Chemomab (NASDAQ: CMMB ) today. CMMB stock is moving higher because Chemomab has good news on the regulatory front, plus the company expects to move forward with important clinical research.

08:25 10 Dec 2023 CMMB

Chemomab Therapeutics stock soars after FDA clears IND for SSc treatment

Shares of Chemomab Therapeutics Ltd. CMMB, -0.51% shot up 46.9% in premarket trading Tuesday, after the Israel-based biotechnology company said the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application to evaluate its systemic sclerosis (SSc) treatment, CM-101.

12:00 10 Dec 2023 CMMB

Chemomab Therapeutics Ltd. (CMMB) Q3 2022 Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Don Marvin - Chief Financial Officer, Executive Vice President and Chief Operating Officer Adi Mor - Co-Founder and Chief Scientific Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab's Third Quarter 2022 Earnings Conference Call.

07:00 10 Dec 2023 CMMB

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

TEL AVIV, Israel , Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in several scientific conferences in November.

02:40 10 Dec 2023 CMMB

Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q2 2022 Results - Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET CompanyParticipants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Operator Greetings Welcome to Chemomab Therapeutics 2022 Second Quarter Earnings Call.

07:00 10 Dec 2023 CMMB

Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update

TEL AVIV, Israel , Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time.

07:00 10 Dec 2023 CMMB

Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference

TEL AVIV, Israel , May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C.

CMMB Financial details

Company Rating

Neutral

Market Cap

6.08M

Income

-33.31M

Revenue

Book val./share

1.98

Cash/share

2.4

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

09 Nov 2023

P/E

-0.16

Forward P/E

-4.45

PEG

-0.01

P/S

P/B

0.25

P/C

0.2

P/FCF

-0.24

Quick Ratio

4.05

Current Ratio

4.06

Debt / Equity

0.01

LT Debt / Equity

EPS (TTM)

-2.96

EPS next Y

-0.11

EPS next Q

2.09

EPS this Y

100.83%

EPS next Y

-96.45%

EPS next 5Y

-96.62%

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-8.86%

SMA20

-23.53%

SMA50

-45.26%

SMA100

-62.59%

Inst Own

0.1%

Inst Trans

ROA

-115%

ROE

-102%

ROC

-1.55%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

12.4M

Shs Float

10.05M

Target Price

52W Range

0.43-5.35

52W High

52W Low

RSI

35.69

Rel Volume

0.18

Avg Volume

1.33M

Volume

235.54K

Perf Week

-12.45%

Perf Month

-40.27%

Perf Quarter

-71.84%

Perf Half Y

-71.18%

Beta

-0.285

Volatility

0.02%, 0.1%

Prev Close

2.06%

Price

0.49

Change

1.66%

CMMB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	0	0.79	-0.54	-1.21	-2.43
Operating cash flow per share	0	-0.48	-0.48	-1.19	-1.79
Free cash flow per share	0	-0.48	-0.48	-1.22	-1.8
Cash per share	0	0.51	1.06	5.9	3.51
Book value per share	0	0.43	0.98	5.93	3.18
Tangible book value per share	0	0.43	0.98	5.93	3.18
Share holders equity per share	0	0.43	0.98	5.93	3.18
Interest debt per share	0	0.16	0.04	0.03	0.05
Market cap	0	771.59M	304.56M	71.58M	36.41M
Enterprise value	14.74M	755.13M	293.31M	57.23M	23.11M
P/E ratio	0	28.45	-51.36	-5.7	-1.32
Price to sales ratio	0	0	0	0	0
POCF ratio	0	-46.88	-58.1	-5.78	-1.79
PFCF ratio	0	-46.61	-57.68	-5.67	-1.78
P/B Ratio	0	51.75	28.19	1.16	1.01
PTB ratio	0	51.75	28.19	1.16	1.01
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	1.16	27.84	-49.31	-4.63	-0.81
EV to operating cash flow	-1.73	-45.88	-55.95	-4.63	-1.13
EV to free cash flow	-1.73	-45.62	-55.55	-4.54	-1.13
Earnings yield	0	0.04	-0.02	-0.18	-0.76
Free cash flow yield	0	-0.02	-0.02	-0.18	-0.56
Debt to equity	0	0.07	0.04	0.01	0.01
Debt to assets	0	0.06	0.03	0.01	0
Net debt to EBITDA	1.16	-0.61	1.89	1.16	0.47
Current ratio	0	4.42	9	23.66	6.18
Interest coverage	0	6.42	0	0	-80.83
Income quality	0	0.61	0.88	0.99	0.74
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0.01	0.01	0.02	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	-0.34	-1.58	-7.03	-1.17
Stock based compensation to revenue	0	0	0	0	0
Graham number	0	2.77	3.45	12.7	13.19
ROIC	0	1.58	-0.51	-0.2	-0.76
Return on tangible assets	-0.9	1.37	-0.48	-0.2	-0.64
Graham Net	0	0.38	0.89	3.44	2.93
Working capital	-14.74M	14.09M	10.52M	60.04M	34.99M
Tangible asset value	-14.74M	14.91M	10.8M	61.47M	36.22M
Net current asset value	-14.74M	13.37M	10.17M	59.8M	34.9M
Invested capital	0	0.07	0.04	0.01	0.01
Average receivables	0	204K	241K	800.5K	993K
Average payables	0	0	46.5K	714.5K	1.51M
Average inventory	0	0	-328.5K	-24.08M	-23.75M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0	1.82	-0.55	-0.2	-0.76
Capex per share	0	0	0	-0.02	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-0.54	-0.73	-0.72	-0.79	-0.72
Operating cash flow per share	-0.5	-0.46	-0.5	-0.65	-0.68
Free cash flow per share	-0.5	-0.46	-0.5	-0.65	-0.68
Cash per share	4.53	4.06	3.49	2.96	2.4
Book value per share	4.54	3.9	3.17	2.53	1.98
Tangible book value per share	4.54	3.9	3.17	2.53	1.98
Share holders equity per share	4.54	3.9	3.17	2.53	1.98
Interest debt per share	-0.02	0.04	0.05	-1.59	0.01
Market cap	42.21M	28.48M	36.6M	17.57M	14.63M
Enterprise value	32.61M	17.99M	23.3M	-3.02M	4.39M
P/E ratio	-1.7	-0.86	-1.11	-0.5	-0.46
Price to sales ratio	0	0	0	0	0
POCF ratio	-7.4	-5.42	-6.42	-2.44	-1.95
PFCF ratio	-7.39	-5.38	-6.42	-2.44	-1.95
P/B Ratio	0.81	0.64	1.01	0.63	0.67
PTB ratio	0.81	0.64	1.01	0.63	0.67
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-5.23	-2.17	-2.7	0.33	-0.54
EV to operating cash flow	-5.72	-3.42	-4.09	0.42	-0.59
EV to free cash flow	-5.71	-3.4	-4.08	0.42	-0.59
Earnings yield	-0.15	-0.29	-0.23	-0.5	-0.54
Free cash flow yield	-0.14	-0.19	-0.16	-0.41	-0.51
Debt to equity	0.01	0.01	0.01	0.01	0.01
Debt to assets	0	0	0	0.01	0
Net debt to EBITDA	1.54	1.26	1.54	2.28	1.25
Current ratio	12.48	8.9	6.18	4.83	4.06
Interest coverage	13.03	-35.09	-22.74	0.51	0
Income quality	0.92	0.65	0.69	0.82	0.94
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0.01	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.79	-2.47	-0.07	-0.06	-0.13
Stock based compensation to revenue	0	0	0	0	0
Graham number	7.45	7.99	7.18	6.71	5.67
ROIC	-0.11	-0.19	-0.24	-0.32	-0.37
Return on tangible assets	-0.11	-0.17	-0.19	-0.25	-0.28
Graham Net	2.37	2.06	2.92	1.8	1.85
Working capital	50.44M	43.25M	34.99M	26.78M	20.88M
Tangible asset value	51.84M	44.62M	36.22M	27.95M	21.99M
Net current asset value	50.29M	43.13M	34.9M	26.72M	20.85M
Invested capital	0.01	0.01	0.01	0.01	0.01
Average receivables	2.52M	2.68M	1.36M	727K	1.02M
Average payables	1.46M	1.34M	1.47M	1.95M	2.28M
Average inventory	-45.23M	-41.47M	-18.99M	-6.47M	-6.47M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	20.62	13.49	0	22.05	0
Days of inventory on hand	-646.82	-411.03	0	-128.66	0
Receivables turnover	0	0	0	0	0
Payables turnover	4.36	6.67	0	4.08	0
Inventory turnover	-0.14	-0.22	0	-0.7	0
ROE	-0.12	-0.19	-0.23	-0.31	-0.36
Capex per share	0	0	0	0	0

CMMB Frequently Asked Questions

What is Chemomab Therapeutics Ltd. stock symbol ?

Chemomab Therapeutics Ltd. is a IL stock and trading under the symbol CMMB

What is Chemomab Therapeutics Ltd. stock quote today ?

Chemomab Therapeutics Ltd. stock price is $0.49 today.

Is Chemomab Therapeutics Ltd. stock public?

Yes, Chemomab Therapeutics Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.33M
Market Capitalization 6.08M
Employee 20
CEO Dr. Adi Mor George Ph.D.
Headquarters Tel Aviv,IL
IPO Date 2019-02-12
Website https://www.chemomab.com

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.